Global Liquid Biopsies Market is anticipated to
reach 5,958.3 million by 2030,
according to a new report by Grand View Research, Inc. As these less invasive
biopsies are able to address a number of significant challenges associated with
conventional biopsies such as, high level of invasiveness, incompleteness of
cancer information that is acquired, associated post-biopsy serious medical
complications, and subsequent cost inclusions. A growing need for more
advanced, efficient and accurate method which provides a holistic view of the
tumor and metastasis is the prime factor fueling rapid development of liquid
biopsies.
The market has gained considerable traction in the past couple of years.
A number of clinical research projects related to circulating tumor cells, and
cell-free tumor DNA have been initiated in the latter half of the past decade.
As a result, there are a number of ongoing clinical trials that are due to be
completed between post 2017-18. It is expected that upon successful completion,
commercialization of these assays and tests will provide the market a
significant boost in potential addressable target revenue and fuel growth
through to 2030.
Full
Research Report on Global Liquid Biopsy Market Analysis:
Further
key findings from the report suggest:
- In terms
of applications, therapy selection of metastatic cancers is the key area of
liquid biopsy usage as these provide significant insights into the unique
genetic information encoded in CTCs and ctDNAs. Furthermore, with the
addition of more research data reinforcing the usage of liquid biopsies
over the coming years, it is expected that their application for molecular
monitoring of diseases will also be a lucrative source of revenue through
to 2030
- Key
biomarkers that any liquid biopsy targets include circulating tumor cells,
circulating tumor DNA and exosomes that are macrovesicles containing tumor
RNA, or tumor protein freely circulating in the patient’s bloodstream.
Assays for ctDNA are expected to account for the largest share of revenue
through to 2030 owing to the currently present assays and expected number
of products that are to be commercialized over the coming decade.
- Development
of parallel multi-gene analysis using next generation sequencing
technology is the underlying factor that has enabled oncologists to more
efficiently sequence ctDNA and gain insights related to cancer metastasis
and the related mechanism. This understanding provides a patient-centric
systemic view of cancer and aids in its long term monitoring.
- North
America, specifically the U.S. accounts for the largest share of revenue
for the development of liquid biopsy market. The region was observed to
account for around 50% of the global potential in 2015 owing to the high
number clinical development projects underway for the commercialization of
CTC and ctDNA assays till 2020. Furthermore, throughout the forecast
period, U.S. is expected to dominate revenue generation owing to the
dynamic nature & being the region of prime activity, research and
development with respect to liquid biopsy and next generation sequencing
technology.
- Although,
post successful commercialization through to 2030, Asia Pacific is
expected to be a lucrative region for development as it is expected to be
characterized by the presence of a large patient population base,
developing healthcare framework and growth in integration of more advanced
healthcare practices.
- The
market is in its developing phase and is characterized by the presence of
a number of relatively smaller entities involved in innovation and new
product development. Companies such as Biocept, Adaptive Biotechnologies,
NeoGenomics Laboratories, Guardant Health, Qiagen, Personal Genome
Diagnostics, Cynvenio, RainDance Technologies, and Trovagene are operating
in the space and have a number of commercialized assays in their
portfolios for liquid biopsy.
- Furthermore,
as this space has a high lucrative potential, and is considerably
influenced by the developments in NGS technology, there are a number of
major players that have ongoing investigational & observational
clinical trials and are due to be completed by 2017 to 2019. Collectively,
over 30 clinical trials are currently registered as active by companies
including Illumina, Foundation Medicine, Natera Inc., Roche, Sequenom,
LabCorp, Epic Sciences, and Pathway Genomics in the U.S. alone.
Anticipated successful commercialization of these products is expected to
fuel growth over the forecast period.
View more
reports of this category by Grand View Research at: http://www.grandviewresearch.com/industry/biotechnology
Grand View
Research has segmented the Global Liquid Biopsy Market on the basis of
application, sample type, biomarker, technology, and region:
Global
Liquid Biopsy Outlook, by Application (Revenue, USD Million, 2013 - 2030)
- Therapy
Selection for Metastatic Breast Cancer (MBS)
- Therapy
Selection for Other Metastatic Cancer
- Molecular
Health Monitoring
Global
Liquid Biopsy, by Sample Type (Revenue, USD Million, 2013 - 2030)
- Blood
Sample based
- Urine
Sample based
- Other Bio
Fluids (Tissue fluids and Saliva) based
Global
Liquid Biopsy Outlook, by Biomarker, (Revenue, USD Million, 2013 - 2030)
- Circulating
Tumor Cells (CTC)
- Circulating
Tumor DNA (ctDNA)
- Exosomes
Global
Liquid Biopsy Outlook, by Biomarker, (Revenue, USD Million, 2013 - 2030)
- Multi -
gene - parallel Analysis (NGS)
- Single
Gene Analysis (PCR Microarrays)
Global
Liquid Biopsy Market, Regional Outlook (Revenue, USD Million, 2013 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Brazil
- MEA
- South
Africa
View press
release of this research report by Grand View Research:
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more
information: www.grandviewresearch.com
No comments:
Post a Comment